SCHEMBL23328703

SCHEMBL23328703

C=CC(=O)N1CCC2(CC1)CCN(C(C)(C)C)C2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.40
TET3 O43151 8/20 0.40
FBXL19 Q6PCT2 8/20 0.40
KDM2B Q8NHM5 8/20 0.40
CXXC4 Q9H2H0 8/20 0.40
KDM2A Q9Y2K7 8/20 0.40
CXXC5 Q7LFL8 7/20 0.40
TET1 Q8NFU7 6/20 0.40
HSD11B1 P28845 1/20 0.37
BTK Q06187 4/20 0.33
USP2 O75604 1/20 0.33
TEC P42680 1/20 0.31
TXK P42681 1/20 0.31
ITK Q08881 1/20 0.31
JAK3 P52333 3/20 0.31
TEAD1 P28347 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21707127 0.94 BTK (0.37) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL23328553 0.92 KMT2A (0.41) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL16075250 0.90 JAK3 (0.35) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL23179807 0.85 BTK (0.35) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL21287863 0.80 ALDH1A1 (0.45) KMT2AHSD11B1USP2
SCHEMBL16075261 0.80 JAK3 (0.36) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL17773331 0.79 HRH3 (0.38) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL20849781 0.79 TET3 (0.45) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL19889017 0.78 HSD11B1 (0.46) KMT2ATET3FBXL19KDM2BCXXC4
SCHEMBL18806125 0.75 HSD11B1 (0.38) KMT2AHSD11B1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 KMT2A 3253/4885TET3 4452/4885FBXL19 1700/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 KMT2A 3272/4885TET3 4625/4885FBXL19 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.